EVENT BROCHURE

IMAPAC
IMAGINE YOUR IMPACT

BIOLOGICS MANUFACTURING ASIA 2027

ASIA'S #1 BIOPROCESSING EVENT

Celebrating 14 Years of Unmatched Excellence

23 - 24 March 2027

Sands Expo & Convention Centre
Singapore

PART OF BIOPHARMA APAC CONFEX
BIOPHARMA ASIA PACIFIC CONFERENCE, EXHIBITION & AWARDS
MULTIPLE MODALITIES. DECISION-MAKERS ONLY
MANUFACTURING | ADC | CGT | CLINICAL TRIALS | OLIGOS & PEPTIDES | SUPPLY CHAIN

Table of Contents

TESTIMONIALS	3
About the Event	4
Sponsors & Media Partners	5
2027 Speakers	7
Agenda at a Glance	8
Agenda	10
Awards & Recognition	26
Expected Audience Snapshot	27
Who Should Sponsor?	28
Why Sponsor This Event?	28
Our Past Partners	29
Add to Calendar	30
Registration Form	31
About IMAPAC	33

EVENT CONTACTS

HEAD OF PRODUCTION

Lara Santiago
lara.santiago@imapac.com
+639176210686

SENIOR CONFERENCE PRODUCER

Melina Dass
melina.dass@imapac.com
+6562303594

BUSINESS DEVELOPMENT MANAGER

Ana Laxamana
ana.laxamana@imapac.com
+6569836132

Nathan Grace Niño
nathan.grace@imapac.com
+6569836134

EVENT HIGHLIGHTS

2,000+	500+	120+
ATTENDEES	COMPANIES	SPEAKERS

DATE & VENUE

23 - 24 March 2027

Sands Expo & Convention Centre
Singapore

CO-LOCATED EVENTS

BIOSUPPLY CHAIN ASIA 2027
CLINICAL TRIALS FESTIVAL ASIA 2027
ADC ASIA CONGRESS 2027
CELL & GENE THERAPY WORLD ASIA 2027
OLIGOS & PEPTIDES WORLD ASIA 2027

AWARDS

ASIA-PACIFIC BIOPHARMA EXCELLENCE AWARDS 2027

Testimonials

The conference provides a forum for latest sharing and networking among biopharma peers from different organisations. The panel discussions are particularly informative as they cover realistic, contemporaneous and first-hand sharing on opportunities and challenges facing the industry and organisations. One key highlight of the conference is the ABEA Night. This prestigious recognition highlights the outstanding contributions of individual leader advancing biopharma excellence in the Asia-Pacific region.

Vice President & Site Quality Head, Global Quality
Takeda
Singapore

It was a very valuable conference experience. I was pleased to have the opportunity to present and discuss our technology with peers in the field, which led to several new and meaningful engagements. The meeting also offered a strong scientific programme, and it was inspiring to hear high-quality work from other groups. Beyond the content itself, the conference was especially useful for building new connections and opening the door to potential future collaborations.

CTO
Singzyme
Singapore

Thank you so much for organizing such a well-run event. It was truly a pleasure to contribute, and I enjoyed the atmosphere and engagement from the audience during the event.

Corporate Performance Specialist
Biofarma
Indonesia

Overall, we believe the event was very well organized and successful. From an exhibitor's perspective, the arrangement of 1-to-1 meetings was particularly useful and added significant value.

Business Development Director
Pfanstiehl
Singapore

Insights from industry leaders are valuable and cannot be found easily online

Technical Steward
BioNTech
Singapore

Thanks for organizing BioSupply Chain Asia, it was a good event and I have learnt a lot.

Head of Singapore Explore Platform
Sanofi
Singapore

The team was very friendly and helpful. They were committed to scheduling 1-to-1 meetings and ensuring it went smoothly.

BDM
SGS
Singapore

Good team, clever techniques to bring people in contact. Appreciate their effort and help.

Product & Sales Manager
DrM Group
Switzerland

About the Event

The 14th Annual Biologics Manufacturing Asia 2027 is Asia's premier bioprocessing-focused conference, providing a dedicated platform for regional biopharmaceutical industry stakeholders to network, explore strategic collaborations, and gain insights into the latest manufacturing technologies and advancements.

This year's agenda is designed to highlight success stories from Asia's leading biopharma companies while incorporating technical expertise from global biopharma leaders, top pharmaceutical companies, and regulators. Key topics will include cutting-edge manufacturing technologies such as single-use systems and end-to-end continuous processing, challenges and opportunities in biomanufacturing, advancements in upstream process development, cost optimization and timeline reduction in downstream processing, analytical characterization strategies, facility design and scale-up, emerging biologics manufacturing technologies, regulatory updates, and novel biologics modalities.

WHAT WE'LL COVER

Key Themes

Cutting-Edge Manufacturing Technologies

Explore innovations in single-use and stainless-steel bioreactor systems, hybrid manufacturing platforms, continuous bioprocessing and next-generation technologies driving greater productivity, scalability and manufacturing efficiency.

Process Development & Optimization

Gain practical insights into upstream and downstream process improvements, from cost reduction to timeline acceleration, to ensure your biologics pipeline stays competitive and robust.

Regulatory & Compliance Updates

Stay ahead of changing regulations with updates from international regulators and big pharma, ensuring you meet evolving requirements and quality standards across Asian markets.

Novel Modalities & Future Opportunities

Discover new opportunities in manufacturing advanced biologics and novel modalities, and learn how to overcome current challenges to unlock the full potential of next-generation therapies.

Strategic Collaboration & Networking

Connect with Asia's top biopharma leaders and global experts through a carefully curated networking platform designed to spark strategic partnerships and drive meaningful industry collaborations

Sponsors & Media Partners

PLATINUM SPONSOR

cytiva

GOLD SPONSORS

BD

WuXi Biologics
Global Solution Provider

SILVER SPONSORS

Pfanstiehl

SARTORIUS

ThermoFisher SCIENTIFIC

BRONZE SPONSOR

ANDGEL

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

EXHIBITORS

ASSOCIATE SPONSORS

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

2027 SPEAKERS

Teck Chung Chang
VP, Site Quality Head
Takeda
SINGAPORE

Prof. Waranyoo Phoolcharoen
CTO & Co-Founder
Baiya Phytopharm Co., Ltd
THAILAND

Dr. Miles Shi
Chief Technology Officer
Etana Biotechnologies
INDONESIA

Sandeep Majumdar
Executive Vice President, Zydus Biologics
Zydus Group
INDIA

Vighnesh Balla
Head of Site Engineering and Maintenance
Sanofi
SINGAPORE

AGENDA AT A GLANCE

DAY 1 | TUESDAY, 23 MARCH 2027

BIOLOGICS MANUFACTURING ASIA 2027

TRACK 1	TRACK 2
Leadership Panel Discussion Building Asia's Global Leadership in Biologics Manufacturing & Innovation	
MORNING TEA BREAK | EXHIBITION VIEWING & 1-1 NETWORKING	
Upstream Processing Robust Cell Lines & Optimized Expression Systems	**Downstream Processing** Advancing Final Product Quality: Polishing, Viral Clearance & Formulation
LUNCH BREAK | EXHIBITION VIEWING & 1-1 NETWORKING	
Upstream Processing Process Intensification Strategies: Perfusion, Fed-Batch & High-Density Strategies	**Analytics & Characterization** Next-Generation Methods for Product Quality & Process Excellence
AFTERNOON TEA BREAK | EXHIBITION VIEWING & 1-1 NETWORKING	
Downstream Processing Refining Primary Recovery: Product Capture, Impurity Removal & Novel Methods	**MSAT & Tech Transfer Excellence** Scale-Up, Validation & Lifecycle Management
ASIA PACIFIC BIOPHARMA EXCELLENCE AWARDS 2027 | GALA DINNER	

AGENDA AT A GLANCE

DAY 2 | WEDNESDAY, 24 MARCH 2027

BIOLOGICS MANUFACTURING ASIA 2027

TRACK 1	TRACK 2
CMC, Analytics & Quality Achieving CMC Excellence, Integrated Analytics, Quality Control & Regulatory Readiness	
MORNING TEA BREAK | EXHIBITION VIEWING & 1-1 NETWORKING	
Formulation, Development & Manufacturing Stability, Drug Product Design & Commercialization	**Smart, Agile and Digital Manufacturing** Flexible Facilities, Digital First Operations and Single Use System
LUNCH BREAK | EXHIBITION VIEWING & 1-1 NETWORKING	
Process Analytics & Real-Time Manufacturing PAT, Advanced Monitoring & Real-Time Release	**Facility Engineering & Infrastructure Excellence** Designing, Operating & Future-Proofing Next-Generation Biomanufacturing Facilities
AFTERNOON TEA BREAK | EXHIBITION VIEWING & 1-1 NETWORKING	

Closing Roundtable Discussion

Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia

Biologics Manufacturing Asia

- Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
- Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
- CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?

ADC Asia Congress

- Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
- From Bench to Bedside: What's Missing in Translating Preclinical ADC Wins to Clinical Success?
- Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities

BioSupply Chain Asia

- Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
- Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
- Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?

Clinical Trial Asia

- Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
- Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?

Oligos & Peptides Asia

- Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
- Beyond Purity: Managing Peptide Aggregation, Degradation & Stability

END OF CONFERENCE

CONFERENCE AGENDA

Day 1

Tuesday, 23 March 2027

Track 1	Track 2

8:50 **IMAPAC Opening Remarks**

8:55 **Chairman Opening Remarks**

TRACK

Building Asia's Global Leadership in Biologics Manufacturing & Innovation

9:00

Leadership Panel Discussion: Asia's Biologics Ambition: From Regional Manufacturing Hub to Global Innovation Powerhouse

- Evaluating Asia's competitive advantage in biologics development, manufacturing, and commercialization.
- Identifying critical investments required in talent, infrastructure, and technology to compete globally.
- Strengthening regional collaboration between governments, industry, academia, and investors.
- Building resilient and future-ready biologics ecosystems capable of supporting next-generation therapeutics.

Teck Chung Chang
VP, Site Quality Head, Takeda

9:50

Accelerating Biologics Manufacturing: Powering Asia's Global Leadership

- Leveraging next-generation technologies to accelerate biologics development and scale-up.
- Advancing upstream, downstream and analytical capabilities for greater efficiency and quality.
- Using automation, AI and digital tools to strengthen manufacturing performance.
- Building Asia's competitiveness as a global biologics manufacturing hub.

Reserved for Solution Providers

Track 1 | Track 2

10:05

Advancing Biologics Development: Enhancing Speed, Quality and Commercial Readiness

- Implementing platform-based approaches to accelerate biologics development timelines.
- Improving cell line development, process development, and analytical characterization strategies.
- Managing technology transfer and global manufacturing network expansion.
- Balancing innovation, cost-efficiency, and regulatory compliance throughout product development.

Sandeep Majumdar
Executive Vice President, Zydus Biologics, Zydus Group

10:30

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking

TRACK
Upstream Processing — Robust Cell Lines & Optimized Expression Systems

11:15

Engineering Next-Generation Cell Lines for High Productivity, Stability & Product Quality

- Balancing productivity, genetic stability, and critical quality attributes (CQAs) during cell line development.
- Leveraging CRISPR, targeted integration, and host cell engineering to create robust production cell lines.
- Strategies to address difficult-to-express proteins, bispecific antibodies, and novel biologic modalities.
- Accelerating clone selection and characterization while maintaining regulatory compliance and manufacturability

TRACK
Downstream Processing — Advancing Final Product Quality: Polishing, Viral Clearance & Formulation

11:15

Doing More with Less: Reducing Buffers, Water, Resin and Waste in Downstream Processing

- Addressing the growing buffer and water footprint of large-scale biologics purification.
- Exploring buffer concentrates, inline conditioning and alternative chromatography approaches.
- Extending resin lifetime while maintaining cleaning effectiveness and product quality.
- Connecting DSP sustainability improvements with manufacturing cost and facility capacity objectives.

Track 1

11:40

AI, Automation & Digital Cell Line Development: Accelerating the Path to High-Producing Clones

- How AI and machine learning are transforming clone selection, cell line screening, and process optimization.
- Digital platforms, automated single-cell cloning, and high-throughput technologies enabling faster development cycles.
- Using predictive analytics to improve manufacturability, productivity, and product quality outcomes.
- Case studies demonstrating reduced timelines and increased success rates through digitalized cell line development

Reserved for Solution Providers

11:55

Enhancing Upstream Productivity Through Advanced Media and Feed Optimization

- Designing chemically defined media for improved cell performance.
- Optimizing feeding strategies to maximize yield and viability.
- Leveraging metabolomics for media development.
- Real-world examples of process intensification through media optimization.

Track 2

11:40

Polishing Under Pressure: Removing HCPs, Aggregates and Process-Related Impurities at Higher Titres

- Designing robust polishing strategies for increasingly concentrated and complex feed streams.
- Tackling difficult-to-remove host cell proteins, DNA, aggregates and leachables.
- Optimising resin selection, loading capacity and operating conditions to reduce purification cycles.
- Applying advanced analytics to understand impurity behaviour and strengthen clearance validation

Reserved for Solution Providers

11:55

Formulation at Higher Concentrations: Solving Stability, Viscosity and Aggregation Challenges

- Developing high-concentration formulations for subcutaneous and patient-friendly delivery.
- Managing viscosity, aggregation, particle formation and protein–protein interactions.
- Optimising excipient selection and formulation conditions to preserve long-term stability.
- Integrating formulation development earlier with upstream and downstream process development.

12:20

Lunch – Exhibition Viewing & 1-1 Networking

Track 1

TRACK
Upstream Processing: Process Intensification Strategies: Perfusion, Fed-Batch & High-Density Strategies

2:05

Beyond Titre: Redefining Upstream Productivity Through High-Density Process Intensification

- Benchmark perfusion, intensified fed-batch and conventional fed-batch across titre, volumetric productivity and facility throughput.
- Optimise cell-specific productivity, viable cell density and culture longevity without compromising CQAs.
- Manage oxygen transfer, CO_2 accumulation, osmolality and nutrient limitations at ultra-high cell densities.
- Determine when higher upstream productivity translates into lower COGS and smaller manufacturing footprints.

Track 2

TRACK
Analytics & Characterization: Next-Generation Methods for Product Quality & Process Excellence

2:05

Multi-Attribute Methods 2.0: Moving MAM from Characterization into Routine QC and Product Release

- Expanding LC-MS-based MAM from development laboratories toward QC environments for simultaneous monitoring of multiple product quality attributes.
- Tackling method robustness, validation, data processing and comparability challenges associated with routine MAM implementation.
- Evaluating how MAM can complement or replace conventional analytical assays without increasing regulatory risk.
- Building regulatory confidence and harmonised implementation strategies across differing APAC market requirements.

Track 1

2:30

Intensified Fed-Batch 2.0: Pushing Cell Density Without Pushing Process Risk

- Design high-density seed trains and N-1 perfusion strategies to shorten production bioreactor occupancy.
- Optimise inoculation density, feeding profiles and metabolic control for accelerated production cycles.
- Prevent lactate, ammonia and other inhibitory metabolite accumulation at elevated biomass levels.
- Evaluate the productivity-versus-complexity trade-off compared with full perfusion.

Reserved for Solution Provider

2:45

Intensification Without Compromise: Controlling CQAs in High-Density and Continuous Cultures

- Understand how prolonged culture duration and altered cellular metabolism influence glycosylation, charge variants and aggregation.
- Define CPP–CQA relationships specifically for perfusion and high-density processes.
- Establish comparability strategies when transitioning commercial molecules from conventional fed-batch to intensified platforms.
- Build control strategies that satisfy evolving expectations for continuous and intensified biomanufacturing in APAC.

Track 2

2:30

AI-Enabled Analytical Development: From Data-Rich Experiments to Faster Quality Decisions

- Applying AI/ML to analytical method development, optimization, and interpretation of complex datasets.
- Connecting PAT, process, and laboratory data to identify emerging quality trends.
- Using predictive analytics to anticipate deviations, OOS/OOT results, and process drift.
- Addressing model validation, data integrity, explainability, and regulatory acceptance across APAC

Reserved for Solution Provider

2:45

Next-Generation Impurity Analytics: Detecting the Unknowns Before They Become a Quality Risk

- Advancing detection and quantification of host-cell proteins, residual DNA, aggregates, fragments, process-related impurities and product variants.
- Applying high-resolution MS, NGS and orthogonal analytical technologies to detect low-abundance and previously unidentified impurities.
- Connecting impurity profiles with upstream and downstream process parameters to improve root-cause analysis and clearance strategies.
- Developing risk-based impurity control strategies that remain robust through process changes, scale-up and technology transfer.

Track 1

3:10

Breaking the Density Barrier: Engineering Robust High-Cell-Density Cultures at Commercial Scale

- Optimising cell-line performance, media composition, feeding strategies, and process parameters at ultra-high cell densities.
- Addressing oxygen transfer, CO_2 accumulation, osmolality, metabolite build-up, and mixing limitations as density increases.
- Understanding how intensified culture conditions influence CQAs, glycosylation, aggregation, and product consistency.
- Translating high-density performance from development-scale bioreactors into reliable GMP manufacturing.

Reserved for Solution Provider

Track 2

3:10

Beyond Manual Testing: Accelerating Quality Decisions Through Automated Analytics

- Advancing automated sample preparation, testing and data analysis to improve throughput, reproducibility and right-first-time results.
- Integrating robotics, miniaturised assays and high-throughput analytical platforms to accelerate testing across development and commercial manufacturing.
- Connecting laboratory automation with LIMS, ELN and manufacturing systems to enable seamless data flow and faster quality decisions.
- Overcoming APAC implementation barriers around validation, legacy-system integration, workforce readiness and investment justification.

Reserved for Solution Provider

3:25

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Track 1

TRACK
Downstream Processing — Refining Primary Recovery: Product Capture, Impurity Removal & Novel Methods

4:10

Panel Discussion: Driving Down Cost of Goods: Maximising Downstream Productivity, Efficiency & Facility Utilisation

- Optimising resin utilisation, buffer consumption and water demand while maintaining yield, purity and critical quality attributes.
- Leveraging buffer concentrates, inline conditioning and inline dilution to reduce preparation burden, storage requirements and facility complexity.
- Applying downstream process intensification to increase throughput and capacity within brownfield and space-constrained APAC manufacturing facilities.
- Translating DSP improvements into measurable gains in cost per batch, cost per gram, facility utilisation and manufacturing capacity.

Track 2

TRACK
MSAT & Tech Transfer Excellence: Scale-Up, Validation & Lifecycle Management

4:10

Panel Discussion: Tech Transfer Under Pressure: Achieving Right-First-Time Transfer Across APAC Manufacturing Networks

- Identifying hidden gaps between sending-unit process knowledge and receiving-site capabilities
- Assessing equipment, facility, raw-material and analytical differences before transfer execution
- Establishing clear MSAT, process development, quality, engineering and manufacturing ownership
- Developing readiness metrics and stage-gate models to reduce deviations and repeat engineering runs

Track 1

4:40

Smarter Impurity Clearance: Tackling HCP, DNA, Aggregates & Process-Related Contaminants

- Understanding how intensified upstream processes change host-cell protein and impurity profiles.
- Improving removal of HCP, residual DNA, aggregates, leachables and other process-related impurities.
- Applying orthogonal purification strategies to address difficult-to-remove contaminants.
- Using enhanced analytics to understand impurity trajectories and optimise downstream unit operations.

Reserved for Solution Provider

4:55

Capture Chromatography Under Pressure: Extending Resin Lifetime Without Compromising Product Quality

- Optimising Protein A loading, cycling and resin utilisation as titres continue to increase.
- Controlling resin fouling, ligand leaching and performance deterioration over extended campaigns.
- Evaluating high-capacity resins, membranes and alternative affinity technologies to reduce capture bottlenecks.
- Building resin lifecycle and cleaning strategies suited to APAC's growing multi-product manufacturing environment.

Track 2

4:40

From Development to Commercial Scale: De-Risking Biologics Scale-Up Without Losing Process Performance

- Translating small-scale process understanding into robust commercial-scale operating ranges
- Managing scale-dependent CPPs, mass transfer, mixing, shear and bioreactor geometry
- Using engineering runs, scale-down models and risk assessments to predict scale-up failure
- Building MSAT strategies that shorten the path from clinical manufacturing to PPQ

Reserved for Solution Provider

4:55

Scaling Plant-Based Biologics: Translating Alternative Expression Platforms from Development to Commercial Manufacturing

- Translating plant-based expression platforms from R&D into scalable and reproducible biologics manufacturing
- Managing scale-up challenges while maintaining yield, consistency, product quality, and process performance
- Identifying and mitigating manufacturing risks associated with alternative expression platforms during technology transfer and scale-up
- Lessons learned in building manufacturing readiness and scalability for next-generation biologics platforms

Prof. Waranyoo Phoolcharoen
CTO & Co-Founder, Baiya Phytopharm Co., Ltd

Track 1

5:20

Continuous & Intensified Downstream Processing: Moving from Unit Operations to Integrated Purification

- Integrating continuous chromatography, filtration and buffer management into connected downstream workflows.
- Overcoming process-control and equipment-integration challenges associated with continuous manufacturing.
- Using PAT and real-time monitoring to maintain critical quality attributes during intensified processing.
- Determining where continuous downstream processing delivers meaningful productivity and COGS advantages in APAC.

Track 2

5:20

Managing Change Without Revalidating Everything: Smarter Lifecycle & Post-Approval Change Management

- Applying science- and risk-based approaches to determine the validation impact of process changes
- Leveraging established conditions and Post-Approval Change Management Protocols
- Managing equipment, raw-material, scale and site changes without compromising the validated state
- Navigating different APAC expectations for variations and post-approval CMC changes

5:45 **Chairman's Closing Remarks**

5:50 **END OF DAY 1**

6:00 **Cocktails & Networking**

6:30 **Asia Pacific Biopharma Excellence Awards 2027 | Gala Dinner**

CONFERENCE AGENDA

Day 2

Wednesday, 24 March 2027

Track 1	Track 2

8:50 **IMAPAC Opening Remarks**

8:55 **Chairman Opening Remarks**

TRACK

CMC, Analytics & Quality Achieving CMC Excellence, Integrated Analytics, Quality Control & Regulatory Readiness (Combined Track 1 and Track 2)

9:00

Regulatory-Ready CMC: Designing Global Development Programs for FDA, EMA & APAC Expectations

- Building CMC strategies that anticipate evolving requirements across FDA, EMA and key APAC regulators.
- Aligning analytical validation, process validation, comparability and stability strategies for global submissions.
- Managing post-approval changes, manufacturing changes and lifecycle comparability without disrupting supply.
- Strengthening regulatory engagement and documentation to reduce CMC questions, review cycles and approval delays.

9:50

Platform Analytics: Leveraging Analytical Methods Across Products and Development Pipelines

- Establishing platform analytical procedures that can be applied across related molecules, modalities, and product families while maintaining product-specific scientific rigor.
- Streamlining method development, qualification, and validation by leveraging prior analytical knowledge and proven platform capabilities.
- Designing robust bridging and method-transfer strategies across products, manufacturing sites, QC laboratories, and global testing networks.
- Defining the scientific evidence, comparability data, and regulatory justification required to support the use of platform methods across multiple products.

Reserved for Solution Providers

Track 1 | Track 2

10:05

Comparability Under Pressure: Managing CMC Change Across Scale-Up, Tech Transfer & Manufacturing Networks

- Designing comparability strategies for process changes, scale-up, site transfers, and manufacturing expansion.
- Determining when analytical comparability is sufficient and when additional non-clinical or clinical evidence may be required.
- Using orthogonal and advanced characterization methods to demonstrate product consistency.
- Building change management strategies that enable manufacturing flexibility without creating regulatory delays.

10:30

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking

TRACK
Formulation, Development & Manufacturing: — Stability, Drug Product Design & Commercialization

11:15

From Molecule to Medicine: Designing Drug Products for Stability, Delivery & Manufacturability

- Translating molecule characteristics into the right formulation and dosage-form strategy.
- Balancing potency, concentration, viscosity, stability, and patient usability.
- Applying QbD to identify critical quality attributes and formulation design space.
- Avoiding late-stage redesign by integrating manufacturing requirements from the outset.

TRACK
Smart, Agile and Digital Manufacturing — Flexible Facilities, Digital First Operations and Single Use System

11:15

From Fixed to Flexible: Designing Multi-Product Facilities for Asia's Changing Biologics Pipeline

- Designing facilities that can rapidly switch between products, modalities, and batch sizes.
- Balancing ballroom, modular, and traditional facility configurations for different manufacturing needs.
- Minimising changeover time, cross-contamination risk, and production downtime in multi-product environments.
- Building flexibility into utilities, equipment, automation, and process flows without overengineering capacity.

Track 1

11:40

Freeze, Dry or Reformulate? Advancing Lyophilization & Alternative Stability Strategies

- Determining when lyophilization offers advantages over liquid formulations.
- Optimizing freezing, primary drying, secondary drying, and cycle development.
- Applying modeling and PAT to improve lyophilization robustness and cycle efficiency.
- Scaling lyophilization processes while maintaining critical quality attributes and product stability.

Reserved for Solution Providers

11:55

Formulation Under Pressure: Solving Stability Challenges Before They Derail Development

- Identifying degradation pathways and critical stability risks earlier in development.
- Tackling aggregation, oxidation, deamidation, hydrolysis, and other product-specific liabilities.
- Using predictive stability models and accelerated studies to guide formulation decisions.
- Building stability-indicating strategies that support longer shelf life and commercialization.

Track 2

11:40

Single-Use at Scale: Solving Cost, Supply and Sustainability Constraints

- Where single-use technologies deliver the strongest operational and economic advantages versus stainless steel.
- Addressing extractables/leachables, integrity, standardisation, and supplier qualification challenges.
- Reducing dependence on imported consumables through stronger regional supply networks and dual sourcing.
- Tackling plastic waste and developing credible sustainability strategies for disposable manufacturing systems.

11:55

Building Agile Biologics Operations: Balancing Manufacturing Capacity, Cost and Supply Resilience

- Designing flexible manufacturing operations to support multiple biologics products and changing pipeline demands
- Balancing capacity utilization, manufacturing cost, CAPEX and operational efficiency
- Integrating manufacturing, engineering, quality, digitalization and supply chain for more agile operations
- Building supply resilience and facility readiness while scaling biologics manufacturing across Asia

Dr. Miles Shi
Chief Technology Officer, Etana Biotechnologies

Track 1	Track 2

12:20 **Lunch – Exhibition Viewing & 1-1 Networking**

TRACK
Process Analytics & Real-Time Manufacturing: — PAT, Advanced Monitoring & Real-Time Release

2:05

From PAT to RTRT: Building the Roadmap to Real-Time Release in Biologics

- Translating PAT data into defensible real-time release strategies for biologics.
- Connecting CPPs, CQAs and in-process measurements to release decisions.
- Validating PAT models and demonstrating continued model performance.
- Regulatory and operational barriers to moving from conventional QC release to RTRT.

TRACK
Facility Engineering & Infrastructure Excellence: Designing, Operating & Future-Proofing Next-Generation Biomanufacturing Facilities

2:05

From Design to GMP Operations: De-Risking Commissioning, Qualification & Facility Start-Up

- Integrating C&Q requirements from concept and detailed design stages
- Risk-based commissioning and qualification of facilities and utilities
- Improving handover between engineering, validation, quality and operations
- Avoiding common start-up failures that delay GMP readiness and production

Track 1

2:30

Soft Sensors & Virtual Measurements: Predicting What You Cannot Measure In-Line

- Developing soft sensors for CQAs that cannot be directly measured continuously.
- Combining process data, mechanistic models and multivariate analytics.
- Model calibration, validation and lifecycle management across batches and sites.
- Using predictive signals for earlier deviation detection and proactive intervention.

Reserved for Solution Providers

2:45

PAT Across the Bioprocess: Connecting Upstream, Downstream & Product Quality

- Deploying PAT from cell culture and harvest through chromatography and formulation
- Monitoring CQAs and CPPs across interconnected unit operations
- Connecting upstream variability with downstream purification performance
- Building an integrated analytical control strategy instead of isolated PAT applications

Track 2

2:30

Engineering the Cleanroom of the Future: Smarter HVAC, Zoning & Energy Optimization

- Optimizing air-change rates without compromising GMP requirements
- Risk-based cleanroom classification and HVAC zoning
- Applying CFD and dynamic environmental control to facility design
- Reducing HVAC energy consumption and lifecycle operating costs

Reserved for Solution Provider

2:45

Contamination Control by Design: Engineering Facilities for Annex 1 & PIC/S Readiness

- Embedding contamination control strategy into facility layout and engineering design
- Engineering pressure cascades, segregation and personnel/material flows
- Integrating barrier technologies, environmental monitoring and closed processing
- Designing facilities that maintain inspection readiness throughout their operational lifecycle

Track 1

3:10

Digital Twins for Biologics: From Process Simulation to Real-Time Control

- Developing hybrid digital twins using first-principles models and manufacturing data
- Connecting PAT measurements to continuously update process-state estimates
- Predicting deviations, yield and product-quality outcomes before they occur
- Using digital twins for scale-up, process optimization, operator decision support and control

Track 2

3:10

Capacity Without Overbuilding: Engineering the Right Facility for Asia's Next Biologics Pipeline

- Using dynamic capacity modelling to determine facility size and configuration
- Balancing current demand against uncertain future pipeline requirements
- Deciding when to expand, retrofit, modularize or build greenfield capacity
- Avoiding over-engineering while retaining sufficient flexibility for future products and technologies

3:35

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Track 1 | Track 2

TRACK

Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia

4:20

Biologics Manufacturing Asia

- Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
- Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
- CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?

ADC Asia Congress

- Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
- From Bench to Bedside: What's Missing in Translating Preclinical ADC Wins to Clinical Success?
- Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities

BioSupply Chain Asia

- Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
- Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
- Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?

Clinical Trial Asia

- Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
- Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?

Oligos & Peptides Asia

- Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
- Beyond Purity: Managing Peptide Aggregation, Degradation & Stability

5:20

Chairman's Closing Remarks

5:30

END OF DAY 2

Awards & Recognition

ASIA-PACIFIC BIOPHARMA EXCELLENCE AWARDS 2027

Asia-Pacific Biopharma Excellence Awards 2027

23RD MARCH 2027 | SANDS EXPO & CONVENTION CENTRE, SINGAPORE

The Asia-Pacific Biopharma Excellence Awards (ABEA) 2027 aims to honour exceptional achievements in the Asian biopharma sector, recognizing excellence in bioprocessing, logistics and supply chain management, antibody-drug conjugates (ADC), and clinical trials over the past year. Celebrating the remarkable contributions of leading biopharma professionals, organizations, and technologies, the awards spotlight trailblazing leaders and trendsetters shaping the industry's future while inspiring innovation for tomorrow's biopharma landscape.

Learn More About Our Awards

Expected Audience Snapshot

85%
ATTENDANCE FROM BIOPHARMA, BIG PHARMA, CDMOS & CROS

85%
DECISION MAKERS

BY PROFILE

Asian Biopharma	45%
International Biopharma	20%
CMOs	15%
Academic & Research Institutes	10%
Technology & Service Providers	10%

BY JOB TITLE

VPs & Directors of Process Development	25%
USP & DSP Specialists & Researchers	25%
Head of Quality Assurance & Analytics	20%
Head of Manufacturing & Bioprocessing	15%
Business Development & Marketing	15%

BY GEOGRAPHY

- 25% Korea & Japan
- 18% China, Taiwan & Hong Kong
- 25% Singapore
- 20% Indonesia, Australia, Thailand, India & Malaysia
- 12% USA & Europe

Who Should Sponsor?

- BIOMANUFACTURING SOFTWARE
- CELL CULTURE AND FERMENTATION
- PROCESS OPTIMIZATION
- CRYOPRESERVATION
- HIGH-THROUGHPUT SCREENING
- MICROFLUIDICS
- BIOSENSOR TECHNOLOGY
- GENE THERAPY TECHNOLOGY
- SINGLE-USE TOOLS
- DRUG DELIVERY
- BIOPROCESSING EQUIPMENT
- CELL LINE DEVELOPMENT
- NEXT-GENERATION SEQUENCING
- BIOINFORMATICS
- BIOSENSOR TECHNOLOGY
- AUTOMATION AND ROBOTICS
- 3D BIOPRINTING
- GENE EDITING
- CONTINUOUS MANUFACTURING

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

Our Past Partners

Business Development Manager:
Ana Laxamana · ana.laxamana@imapac.com · +6569836132
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

MARK YOUR CALENDAR

Save the Date

23 - 24 MAR 2027

Sands Expo & Convention Centre

Biologics Manufacturing Asia 2027

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific: biopharmaceutical conferences, summits and exhibitions for the year ahead.

→

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

Registration Form

BIOLOGICS MANUFACTURING ASIA 2027

CATEGORY	EARLY BIRD (By 3 Oct 2026)	REGISTRATION (By 5 Dec 2026)	STANDARD (By 6 Feb 2027)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 4,295	SGD 4,495	SGD 4,695	SGD 4,895

BRING YOUR TEAM - Group Discount

Asia & International Biopharma

☐ Buy 2, Get 3 passes
☐ Buy 3, Get 5 passes

Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes.

INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount.

- Access to all conference proceedings for up to 30 days.
- Site Tour Package is applicable only with the purchase of a conference pass.

Standard Package Group Discount

3 Delegates Save 10% ☐ 5 Delegates Save 20% ☐ 6+ Delegates Save 25% ☐

EVENT VENUE

Sands Expo & Convention Centre
Singapore
23 - 24 March 2027

3 EASY WAYS TO REGISTER

Online
Visit:
https://www.imapac.com/events/biologics-manufacturing-asia-2027

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at https://www.imapac.com/events/biologics-manufacturing-asia-2027#register

Name on Card _____ Card Number _____
Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received.
Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers).
Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

E: ana.laxamana@imapac.com | nathan.grace@imapac.com C: +65 6983 6132 | +65 6983 6134

BIOPHARMA APAC CONFEX
BIOPHARMA ASIA PACIFIC CONFERENCE, EXHIBITION & AWARDS

MANUFACTURING | ADC | CGT | CLINICAL TRIALS | TIDES | SUPPLY CHAIN

THIS EVENT IS PART OF

Biopharma APAC Confex 2027

Multiple Modalities. Decision-Makers Only.

Biopharma APAC Confex is Asia-Pacific's leading biopharma gathering, bringing together 2,000+ attendees and 700+ companies across co-located conferences spanning biologics manufacturing, clinical trials, ADCs, cell & gene therapy, TIDES, and supply chain innovation — supporting collaboration, knowledge sharing, and strategic partnerships across the region.

2000+	700+	250+	72+
ATTENDEES	COMPANIES	SPEAKERS	NETWORKING HOURS

CO-LOCATED CONFERENCES

- CELL & GENE THERAPY WORLD ASIA 2027
- OLIGONUCLEOTIDES & PEPTIDES WORLD ASIA CONGRESS 2027
- CLINICAL TRIALS FESTIVAL ASIA 2027
- ADC ASIA CONGRESS 2027
- BIOSUPPLY CHAIN ASIA 2027
- BIOLOGICS MANUFACTURING ASIA 2027

23–24 March 2027 · Sands Expo & Convention Centre, Singapore · **biopharmaapacconfex.com**

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

IMAPAC
IMAGINE YOUR IMPACT

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd